Structure‐function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  EMBO Journal

• Publication date

  1992-07-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1002/j.1460-2075.1992.tb05315.xPMID 1321034PMCID PMC556725
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor.

  1991cited by this paper
• An alternatively processed mRNA generated from human hepatocyte growth factor gene.

  1991cited by this paper
• Hepatocyte growth factor is a potent mitogen for cultured rabbit renal tubular epithelial cells.

  1991cited by this paper
• Identification of a competitive HGF antagonist encoded by an alternative transcript.

  1991cited by this paper
• Characterization of the DNF15S2 locus on human chromosome 3: identification of a gene coding for four kringle domains with homology to hepatocyte growth factor.

  1991cited by this paper
• Hepatocyte growth factor (hepatopoietin A) rapidly increases in plasma before DNA synthesis and liver regeneration stimulated by partial hepatectomy and carbon tetrachloride administration

  1991cited by this paper
• Identification and change in the receptor for hepatocyte growth factor in rat liver after partial hepatectomy or induced hepatitis.

  1991cited by this paper
• Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor.

  1991cited by this paper
• Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

  1991cited by this paper
• Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET.

  1991cited by this paper
• Hepatocyte growth factor is a potent stimulator of human melanocyte DNA synthesis and growth.

  1991cited by this paper
• Identification of the N-terminal residue of the heavy chain of both native and recombinant human hepatocyte growth factor.

  1991cited by this paper
• Purification and characterization of hepatocyte growth factor from injured liver of carbon tetrachloride-treated rats.

  1991cited by this paper
• Hepatocyte growth factor/hepatopoietin A stimulates the growth of rat kidney proximal tubule epithelial cells (RPTE), rat nonparenchymal liver cells, human melanoma cells, mouse keratinocytes and stimulates anchorage-independent growth of SV-40 transformed RPTE.

  1991cited by this paper
• Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor.

  1991cited by this paper
• Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing

  1991cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Deduced primary structure of rat hepatocyte growth factor and expression of the mRNA in rat tissues.

  1990cited by this paper
• Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte.

  1990cited by this paper
• Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells

  1990cited by this paper
• Calculating receptor number from binding experiments using same compound as radioligand and competitor.

  1989cited by this paper
• Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor.

  1989cited by this paper
• Molecular cloning and expression of human hepatocyte growth factor

  1989cited by this paper
• Purification and partial characterization of hepatocyte growth factor from plasma of a patient with fulminant hepatic failure.

  1988cited by this paper
• Plasminogen activation: biochemistry, physiology, and therapeutics.

  1988cited by this paper
• Structure of native porcine pancreatic elastase at 1.65 A resolutions.

  1988cited by this paper
• Rapid and efficient site-specific mutagenesis without phenotypic selection.

  1987cited by this paper
• Scatter factor is a fibroblast-derived modulator of epithelial cell mobility

  1987cited by this paper
• Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis.

  1987cited by this paper
• Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors.

  1987cited by this paper
• The refinement and the structure of the dimer of alpha-chymotrypsin at 1.67-A resolution.

  1985cited by this paper
• Control of hepatocyte replication by two serum factors.

  1984cited by this paper
• Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats.

  1984cited by this paper
• Partial characterization of a hepatocyte growth factor from rat platelets

  1984cited by this paper
• Direct determination of the protonation states of aspartic acid-102 and histidine-57 in the tetrahedral intermediate of the serine proteases: neutron structure of trypsin.

  1981cited by this paper
• The hormonal control of gluconeogenesis by regulation of mitochondrial pyruvate carboxylation in isolated rat liver cells.

  1975cited by this paper
• On the size of the active site in proteases. I. Papain.

  1967cited by this paper

• Therapeutic potential of tyrosine-protein kinase MET in osteosarcoma

  2024cites this paper
• MET Oncogene Targeting for Cancer Immunotherapy

  2024cites this paper
• Inhibition of autocrine HGF maturation overcomes cetuximab resistance in colorectal cancer

  2024cites this paper
• Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.

  2024cites this paper
• Quantitative live imaging reveals a direct interaction between CD44v6 and MET in membrane domains upon activation with both MET ligands, HGF and internalin B.

  2023cites this paper
• Computer‐Assisted Identification of Inhibitor with Novel Pharmacophore Targeting First Kringle Domain of Hepatocyte Growth Factor

  2023cites this paper
• Correlation between hypoxia and HGF/c-MET expression in the management of pancreatic cancer.

  2023cites this paper
• Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

  2022cites this paper
• Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist

  2022cites this paper
• c-Met-integrin cooperation: Mechanisms, tumorigenic effects, and therapeutic relevance

  2022cites this paper
• A pilot study on nitration/dysfunction of NK1 segment of myogenic stem cell activator HGF

  2022cites this paper
• hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers

  2022cites this paper
• A Novel Humanized Model of NASH and Its Treatment With META4, A Potent Agonist of MET

  2021cites this paper
• Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation

  2021cites this paper
• Identification of other Cellular Receptors for Edema Factor of Bacillus anthracis by Independent Inhibition of Protective Antigen Evidenced by Inhibition of Embryo Growth and Angiogenesis.

  2021cites this paper
• Structural basis of the activation of c-MET receptor

  2021cites this paper
• Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor

  2021cites this paper
• Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.

  2021cites this paper
• State of the structure address on MET receptor activation by HGF.

  2021cites this paper
• Targeting HGF/c-MET Axis in Pancreatic Cancer

  2020cites this paper
• The constitutive high affinity Met binding site in the kringle domain is dispensable for the signaling activity of hepatocyte growth factor.

  2020cites this paper
• CRISPR/Cas12a-mediated labeling of MET receptor enables quantitative single-molecule imaging of endogenous protein organization and dynamics

  2020cites this paper
• GD2‐directed CAR‐T cells in combination with HGF‐targeted neutralizing antibody (AMG102) prevent primary tumor growth and metastasis in Ewing sarcoma

  2020cites this paper
• MET targeting: time for a rematch

  2020cites this paper
• Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent minimal MET receptor agonist

  2020cites this paper
• DDDT_A_224491 4173..4184

  2019cites this paper
• A Noncanonical Role for Plasminogen Activator Inhibitor Type 1 in Obesity-Induced Diabetes.

  2019cites this paper
• Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma

  2019cites this paper
• Activation of Ca2+-activated K+ Channels and Cell Migration by Hepatocyte Growth Factor/Scatter Factor in Madin-Darby Canine Kidney Cells

  2019cites this paper
• Prognostic Role of c-Met Overexpression in High Grade Glioma: a Meta-analysis

  2019cites this paper
• Macrocyclic peptide-based inhibition and imaging of hepatocyte growth factor

  2019cites this paper
• Efficient Selection of Antibodies Reactive to Homologous Epitopes on Human and Mouse Hepatocyte Growth Factors by Next-Generation Sequencing-Based Analysis of the B Cell Repertoire

  2019cites this paper
• The epithelialisation phase in wound healing: options to enhance wound closure.

  2018cites this paper
• The Impact of the Epithelial–Mesenchymal Transition Regulator Hepatocyte Growth Factor Receptor/Met on Skin Immunity by Modulating Langerhans Cell Migration

  2018cites this paper
• Isolation and molecular cloning of hepatocyte growth factor from guinea pig (gHGF), and expression of truncated variant of gHGF with improved anti-fibrotic activity in Escherichia coli.

  2018cites this paper
• Inhibitors of the Growth‐Factor Activating Proteases Matriptase, Hepsin and HGFA: Strategies for Rational Drug Design and Optimization

  2018cites this paper
• HGF Activator (HGFA) and its Inhibitors HAI‐1 and HAI‐2: Key Players in Tissue Repair and Cancer

  2018cites this paper
• MET/HGF Co-Targeting in Pancreatic Cancer: A Tool to Provide Insight into the Tumor/Stroma Crosstalk

  2018cites this paper
• Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• The effect of hepatocyte growth factor on mouse oocyte in vitro maturation and subsequent fertilization and embryo development

  2018cites this paper
• Targeting HGF with Antibodies as an Anti‐Cancer Therapeutic Strategy

  2018cites this paper
• Production of human mutant biologically active hepatocyte growth factor in Chinese hamster ovary cells

  2017influential citation
• Preclinical development of a humanized neutralizing antibody targeting HGF

  2017cites this paper
• Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges

  2017cites this paper
• Targeting the hepatocyte growth factor/Met pathway in cancer.

  2017cites this paper
• Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy

  2017cites this paper
• United States Patent ( 10 ) Patent No . : US 7 , 737 , 115 B 2

  2017cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• A human recombinant IL-7/HGFβ hybrid cytokine enhances antitumor immunity in mice.

  2017cites this paper
• Signalling Pathways in Glioma- Propagating Cells

  2016cites this paper
• Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

  2016cites this paper
• CURRENT PERSPECTIVE OF THERAPIES TO GLIOMAS EXPRESSING HEPATOCYTE GROWTH FACTOR

  2016cites this paper
• Hepatocyte Growth Factor Localization in Primary Glomerulonephritis and Drug-Induced Interstitial Nephritis

  2016cites this paper
• Современные методы коррекции аномалий окклюзии с применением мини-имплантатов и минипластин

  2016cites this paper
• Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling

  2016cites this paper
• Recombinant IL‐7/HGFβ hybrid cytokine separates acute graft‐versus‐host‐disease from graft‐versus‐tumour activity by altering donor T cell trafficking

  2016influential citation
• Usefulness of the Hepatocyte Growth Factor as a Predictor of Mortality in Patients Hospitalized With Acute Heart Failure Regardless of Ejection Fraction.

  2016cites this paper
• HGF-Met シグナル伝達の構造的基盤

  2016cites this paper
• Probing conformational and functional states of human hepatocyte growth factor by a panel of monoclonal antibodies

  2016cites this paper
• Achieving high signal-to-noise in cell regulatory systems: Spatial organization of multiprotein transmembrane assemblies of FGFR and MET receptors

  2015cites this paper
• Characterization of an oncolytic adenovirus vector constructed to target the cMet receptor

  2015cites this paper
• Flexibility and small pockets at protein–protein interfaces: New insights into druggability

  2015cites this paper
• The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases.

  2015cites this paper
• Developing Antagonists for the Met-HGF/SF Protein–Protein Interaction Using a Fragment-Based Approach

  2015cites this paper
• Activation of Ca2+-activated K+ Channels and Cell Migration by Hepatocyte Growth Factor/Scatter Factor in Madin-Darby Canine Kidney Cells

  2015cites this paper
• Direct binding of hepatocyte growth factor and vascular endothelial growth factor to CD44v6

  2015cites this paper
• The MET Receptor Family

  2015cites this paper
• Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.

  2015cites this paper
• Expression array analysis of the hepatocyte growth factor invasive program

  2015cites this paper
• Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy

  2015cites this paper
• Aptamers Binding to c-Met Inhibiting Tumor Cell Migration

  2015cites this paper
• Effets des clivages du récepteur tyrosine kinase Met par les calpaïnes sur la motilité et la mort cellulaire

  2014cites this paper
• High-level expression and characterization of bioactive human truncated variant of hepatocyte growth factor in Escherichia coli

  2014cites this paper
• An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.

  2014cites this paper
• Matriptase mediated c-Met signaling in breast cancer

  2014cites this paper
• Design, synthesis and biological evaluation of novel 6,7-disubstituted-4-phenoxyquinoline derivatives bearing 4-oxo-3,4-dihydrophthalazine-1-carboxamide moieties as c-Met kinase inhibitors.

  2014cites this paper
• Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling

  2014cites this paper
• Mechanisms of Hepatocyte Growth Factor Activation in Cancer Tissues

  2014cites this paper
• Companion Diagnostics & Cancer Biomarkers HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

  2013cites this paper
• HGFasaCirculatingBiomarkerofOnartuzumabTreatmentin Patients with Advanced Solid Tumors

  2013cites this paper
• Prenatal Expression of MET Receptor Tyrosine Kinase in the Fetal Mouse Dorsal Raphe Nuclei and the Visceral Motor/Sensory Brainstem

  2013cites this paper
• Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1.

  2013cites this paper
• Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

  2013influential citation
• HGFasaCirculatingBiomarker ofOnartuzumabTreatment in Patients with Advanced Solid Tumors

  2013cites this paper
• Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.

  2013cites this paper
• HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

  2013cites this paper
• BASIS FOR TARGETING MET ACTIVATION MEDIATED RESISTANCE TO PI3K INHIBITION IN BREAST CANCER

  2013influential citation
• Targeting the HGF/Met signaling pathway in cancer therapy

  2012cites this paper
• Targeting the hepatocyte growth factor-cMET axis in cancer therapy.

  2012cites this paper
• Development of Angiotensin IV Analogs as Hepatocyte Growth Factor/Met Modifiers

  2012cites this paper
• Hepatocyte growth factor: Molecular biomarker and player in cardioprotection and cardiovascular regeneration

  2012cites this paper
• HGF (hepatocyte growth factor (hepapoietin A; scatter factor))

  2012cites this paper
• MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.

  2012cites this paper
• Development of therapeutics targeting the hepatocyte growth factor (HGF)/MET system

  2011influential citation
• The autism risk genes MET and PLAUR differentially impact cortical development

  2011cites this paper
• Induction of HGF and VEGF in hepatic regeneration after hepatotoxin-induced cirrhosis in mice.

  2011cites this paper
• Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists

  2011cites this paper
• Structural insights into Met receptor activation.

  2011cites this paper
• The effect of hepatocyte growth factor on mouse oocyte in vitro maturation and subsequent fertilization and embryo development

  2011cites this paper